Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States

  title={Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States},
  author={Siyang Peng and Ali Gerhard Tafazzoli and Emily D Dorman and Lisa C. Rosenblatt and Angelina Villasis-Keever and Sonja V. Sorensen},
  journal={Journal of Medical Economics},
  pages={763 - 776}
Abstract Objective: Data from the SINGLE trial demonstrated that 88% of treatment-naïve HIV-1 patients treated with dolutegravir and abacavir/lamivudine (DTG + ABC/3TC) achieved viral suppression at 48 weeks compared with 81% of patients treated with efavirenz/tenofovir disoproxil fumarate/emtricitabine (EFV/TDF/FTC). It is unclear how this difference in short-term efficacy impacts long-term cost-effectiveness of these regimens. This study sought to evaluate long-term cost-effectiveness of DTG… 
Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patients
With lower costs, higher response rates and higher QALYs, DTG can be considered as a cost-effective alternative for treatment naive and first-line failure patients in China.
How can we achieve universal access to low-cost treatment for HIV?
Very high baseline HIV viremia impairs efficacy of non-nucleoside reverse transcriptase inhibitor-based ART: a long-term observation in treatment-naïve patients
Very high levels of pre-treatment HIV-RNA were related with delayed efficacy of NNRTI-based ART and increased risk of treatment failure and more potent initial regimens should be considered for those with this clinical character.
Cost considerations in the current antiretroviral era
Of five commonly prescribed regimens for treatment-naïve HIV patients in one clinic (2007–2012), emtricitabine and tenofovir with efavirenz and raltegravir were the only consistently cost-effective options; the rilpivirine-based regimen was valuable in limited scenarios.
Observing the revolution: A commentary on the new GeSIDA HIV guidelines.
Global estimates for the lifetime cost of managing HIV: a systematic review.
Estimating the lifetime costs of managing HIV is useful for budgetary planning and to ensure HIV management is affordable for all and HIV prevention strategies need to be strengthened to avert these high costs.
Health state utilities associated with attributes of migraine preventive treatments based on patient and general population preferences
Results from the patient sample indicate that these treatment characteristics have an impact on patient preference, and utilities estimated from the general population sample may be used to represent route of administration and AEs in cost-utility models.


Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients: Final 5-Year Results From STARTMRK
In this exploratory analysis of combination therapy with tenofovir/emtricitabine in treatment-naive patients at week 240, vRNA suppression rates and increases in baseline CD4 counts were significantly higher in raltegravir than efavirenz recipients.
Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US
Stribild was not cost-effective in the base case compared with Atripla for first-line HIV treatment, and when equivalent efficacy was assumed, AtRIpla dominated Stribild with lower costs and greater QALYs.
Lopinavir/Ritonavir Versus Darunavir Plus Ritonavir for HIV Infection: A Cost-Effectiveness Analysis for the United States
A comprehensive simulation of lifetime course of HIV in the USA indicated that using LPV/r as first-line therapy compared with DRV + RTV may result in cost savings, with similar clinical outcomes.
Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced patients with HIV type 1 infection.
In a real-life setting ATV/r-based regimens demonstrated sustained virologic suppression in ARV-experienced patients and the majority of patients remained on treatment and no unexpected AEs were observed after long-term therapy.
48-Week Efficacy and Safety of Dolutegravir Relative to Commonly Used Third Agents in Treatment-Naive HIV-1–Infected Patients: A Systematic Review and Network Meta-Analysis
Three clinical trials of DTG have demonstrated comparable or superior efficacy and safety to DRV, RAL, and EFV in HIV-1–infected treatment-naive patients, which suggests DTG is also favorable or comparable to other commonly used third agents (ATV/r, LPV/ r, RPV, and EVG/c).
Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN.
At 96 weeks, noninferiority (HIV-1 RNA < 400 copies/mL) of DRV/r over LPV/ r was maintained; the difference in response was statistically significant.
Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96
Treatment with DRV/r 600/100 mg twice daily was well tolerated and led to sustained virological and immunological responses in treatment-experienced HIV-1-infected patients over 96 weeks.
Long-Term Gender-Based Outcomes for Atazanavir/Ritonavir (ATV/r)-Containing Regimens in Treatment-Experienced Patients with HIV
In a clinical setting, long-term efficacy and safety outcomes of ATV/r-based regimens were similar by gender, and women had a higher risk of TD but no increased risk of VF.
Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients: 144-Week Analysis
Cumulative results from 3 years of follow-up suggest that a regimen of TDF/FTC andEFV demonstrates superior durability of viral load suppression and an improved safety and morphologic profile compared with ZDV/3TC and EFV.